DHFR is posttranscriptionally regulated through ADAR1-mediated RNA editing by editing the miR-25-3p and miR-125a-3p binding sites in the 3’-UTR of DHFR, affecting cell proliferation and sensitivity of BC cells to methotrexate. This evidence concerns the gene ADAR and breast cancer.